BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 29480432)

  • 1. Frontline Therapy of CLL: Evolving Treatment Paradigm.
    Boddy CS; Ma S
    Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal management of the young patient CLL patient.
    Allan JN; Furman RR
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):73-82. PubMed ID: 29452669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
    Kojima K; Burger JA
    J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting Frontline Therapy for CLL in 2018.
    Jain N
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
    Rafei H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):1-12. PubMed ID: 28549767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents versus chemotherapy as frontline treatment of CLL.
    Piggin A; Bayly E; Tam CS
    Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Suzumiya J; Takizawa J
    Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents in chronic lymphocytic leukemia.
    Lamanna N; O'Brien S
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
    Mikudina B; Goodall M; Adler AI
    Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
    [No Abstract]   [Full Text] [Related]  

  • 15. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.
    Khan Y; Lyou Y; El-Masry M; O'Brien S
    Expert Rev Hematol; 2020 Jan; 13(1):31-38. PubMed ID: 31756301
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the best frontline therapy for patients with CLL and 17p deletion?
    Badoux XC; Keating MJ; Wierda WG
    Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
    Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.